# CytoDyn Inc.: financial statements, quarterly

CYDY · OTC · CIK 1175680 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31

Pages: [Overview](/companies/cydy.md) · [Financials](/companies/cydy/financials.md) · [Filings](/companies/cydy/filings.md) · [Insiders](/companies/cydy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cydy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.1](/filings/0001558370-24-000305.md) | [0.7](/filings/0001558370-24-005134.md) | [3.6 d](/filings/0001558370-24-012328.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(3.4)](/filings/0001558370-25-000207.md) | [(3.4)](/filings/0001558370-25-004774.md) | [(6.6) d](/filings/0001558370-25-009617.md) | [22.4](/filings/0001104659-25-098552.md) | [(3.7)](/filings/0001104659-26-002335.md) | [(4.0)](/filings/0001104659-26-040687.md) | [(5.1) d](/filings/0001175680-26-000014.md) | [(4.9)](/filings/0001175680-26-000035.md) | [(21.7)](/filings/0001104659-26-002335.md) | [(6.3)](/filings/0001104659-26-040687.md) | [(5.6) d](/filings/0001175680-26-000014.md) | [(6.6)](/filings/0001175680-26-000035.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001558370-25-000207.md) | [0.0](/filings/0001558370-25-004774.md) | [0.0 d](/filings/0001558370-25-009617.md) | [0.0](/filings/0001104659-25-098552.md) | [0.0](/filings/0001104659-26-002335.md) | [0.0](/filings/0001104659-26-040687.md) | [0.0 d](/filings/0001175680-26-000014.md) | [0.0](/filings/0001175680-26-000035.md) | [0.0](/filings/0001104659-26-002335.md) | [0.0](/filings/0001104659-26-040687.md) | [0.0 d](/filings/0001175680-26-000014.md) | [0.0](/filings/0001175680-26-000035.md) |
| Net income | $m | [(9.6)](/filings/0001558370-25-004774.md) | [(11.9)](/filings/0001558370-25-004774.md) | [(16.8) d](/filings/0001558370-25-009617.md) | [19.2](/filings/0001104659-26-040687.md) | [(4.8)](/filings/0001104659-26-040687.md) | [(4.8)](/filings/0001104659-26-040687.md) | [(6.0) d](/filings/0001175680-26-000014.md) | [(5.5)](/filings/0001175680-26-000035.md) | [(22.6)](/filings/0001104659-26-040687.md) | [(4.7)](/filings/0001104659-26-040687.md) | [(9.9) d](/filings/0001175680-26-000014.md) | [(19.9)](/filings/0001175680-26-000035.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001558370-25-000207.md) | [(0.01)](/filings/0001558370-25-004774.md) | not reported | [0.02](/filings/0001104659-25-098552.md) | [0.00](/filings/0001104659-26-002335.md) | [0.00](/filings/0001104659-26-040687.md) | not reported | [0.00](/filings/0001175680-26-000035.md) | [(0.02)](/filings/0001104659-26-002335.md) | [0.00](/filings/0001104659-26-040687.md) | not reported | [(0.01)](/filings/0001175680-26-000035.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001558370-25-000207.md) | [(0.01)](/filings/0001558370-25-004774.md) | not reported | [0.02](/filings/0001104659-25-098552.md) | [0.00](/filings/0001104659-26-002335.md) | [0.00](/filings/0001104659-26-040687.md) | not reported | [0.00](/filings/0001175680-26-000035.md) | [(0.02)](/filings/0001104659-26-002335.md) | [0.00](/filings/0001104659-26-040687.md) | not reported | [(0.01)](/filings/0001175680-26-000035.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.1](/filings/0001558370-25-000207.md) | [1.4](/filings/0001558370-25-004774.md) | [3.1](/filings/0001558370-25-009617.md) | [24.9](/filings/0001558370-24-013320.md) | [21.3](/filings/0001558370-25-000207.md) | [16.4](/filings/0001558370-25-004774.md) | [11.9](/filings/0001175680-26-000014.md) | [9.3](/filings/0001104659-25-098552.md) | [5.0](/filings/0001104659-26-002335.md) | [15.7](/filings/0001104659-26-040687.md) | [11.9](/filings/0001175680-26-000035.md) | [16.4](/filings/0001175680-26-000035.md) |
| Current assets | $m | [8.8](/filings/0001558370-24-000305.md) | [9.9](/filings/0001558370-24-005134.md) | [10.8](/filings/0001558370-25-009617.md) | [27.7](/filings/0001558370-24-013320.md) | [24.6](/filings/0001558370-25-000207.md) | [21.0](/filings/0001558370-25-004774.md) | [17.9](/filings/0001175680-26-000014.md) | [13.4](/filings/0001104659-25-098552.md) | [8.8](/filings/0001104659-26-002335.md) | [18.4](/filings/0001104659-26-040687.md) | [13.9](/filings/0001175680-26-000035.md) | [19.0](/filings/0001175680-26-000035.md) |
| Total assets | $m | [9.2](/filings/0001558370-24-000305.md) | [10.3](/filings/0001558370-24-005134.md) | [11.1](/filings/0001558370-25-009617.md) | [28.0](/filings/0001558370-24-013320.md) | [24.9](/filings/0001558370-25-000207.md) | [21.2](/filings/0001558370-25-004774.md) | [18.0](/filings/0001175680-26-000014.md) | [13.5](/filings/0001104659-25-098552.md) | [8.9](/filings/0001104659-26-002335.md) | [18.5](/filings/0001104659-26-040687.md) | [14.0](/filings/0001175680-26-000035.md) | [19.1](/filings/0001175680-26-000035.md) |
| Current liabilities | $m | [123](/filings/0001558370-24-000305.md) | [129](/filings/0001558370-24-005134.md) | [84.2](/filings/0001558370-25-009617.md) | [69.6](/filings/0001558370-24-013320.md) | [70.6](/filings/0001558370-25-000207.md) | [70.6](/filings/0001558370-25-004774.md) | [70.5](/filings/0001175680-26-000014.md) | [69.4](/filings/0001104659-25-098552.md) | [85.1](/filings/0001104659-26-002335.md) | [50.4](/filings/0001104659-26-040687.md) | [53.7](/filings/0001175680-26-000035.md) | [49.7](/filings/0001175680-26-000035.md) |
| Total liabilities | $m | [124](/filings/0001558370-24-000305.md) | [130](/filings/0001558370-24-005134.md) | [128](/filings/0001558370-25-009617.md) | [113](/filings/0001558370-24-013320.md) | [114](/filings/0001558370-25-000207.md) | [114](/filings/0001558370-25-004774.md) | [114](/filings/0001175680-26-000014.md) | [113](/filings/0001104659-25-098552.md) | [129](/filings/0001104659-26-002335.md) | [123](/filings/0001104659-26-040687.md) | [124](/filings/0001175680-26-000035.md) | [117](/filings/0001175680-26-000035.md) |
| Long-term debt | $m | [45.9](/filings/0001558370-24-000305.md) | [44.2](/filings/0001558370-24-005134.md) | [45.0](/filings/0001558370-25-009617.md) | [45.3](/filings/0001558370-24-013320.md) | [46.1](/filings/0001558370-25-000207.md) | [45.8](/filings/0001558370-25-004774.md) | [45.4](/filings/0001175680-26-000014.md) | [43.8](/filings/0001104659-25-098552.md) | [42.2](/filings/0001104659-26-002335.md) | [40.5](/filings/0001104659-26-040687.md) | [38.3](/filings/0001175680-26-000035.md) | [35.8](/filings/0001175680-26-000035.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(114)](/filings/0001558370-25-004774.md) | [(119)](/filings/0001558370-25-004774.md) | [(117)](/filings/0001175680-26-000014.md) | [(85.2)](/filings/0001104659-26-040687.md) | [(89.4)](/filings/0001104659-26-040687.md) | [(93.0)](/filings/0001104659-26-040687.md) | [(96.0)](/filings/0001175680-26-000035.md) | [(99.5)](/filings/0001175680-26-000035.md) | [(120)](/filings/0001104659-26-040687.md) | [(104)](/filings/0001104659-26-040687.md) | [(110)](/filings/0001175680-26-000035.md) | [(98.1)](/filings/0001175680-26-000035.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,502) d](/filings/0001558370-25-000207.md) | [(2,335) d](/filings/0001558370-25-004774.md) | [(1,650) d](/filings/0001558370-25-009617.md) | [5,440](/filings/0001104659-25-098552.md) | [(3,586) d](/filings/0001104659-26-002335.md) | [(4,956) d](/filings/0001104659-26-040687.md) | [(5,663) d](/filings/0001175680-26-000014.md) | [(2,450)](/filings/0001175680-26-000035.md) | [(4,350) d](/filings/0001104659-26-002335.md) | [(5,519) d](/filings/0001104659-26-040687.md) | [(4,933) d](/filings/0001175680-26-000014.md) | [(7,726)](/filings/0001175680-26-000035.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-11-30) | Q3 FY2023 (2023-02-28) | Q1 FY2024 (2023-08-31) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [813](/filings/0001558370-24-000305.md) | [832](/filings/0001558370-24-005134.md) | [924](/filings/0001558370-24-013320.md) | [959](/filings/0001558370-25-000207.md) | [982](/filings/0001558370-25-004774.md) | [1,198](/filings/0001104659-25-098552.md) | [1,221](/filings/0001104659-26-002335.md) | [1,228](/filings/0001104659-26-040687.md) | [1,253](/filings/0001175680-26-000035.md) | [1,261](/filings/0001104659-26-002335.md) | [1,275](/filings/0001104659-26-040687.md) | [1,382](/filings/0001175680-26-000035.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,469,518,000 at 2026-09-30, from the cover of the [10-Q filed 2026-10-14](/filings/0001175680-26-000035.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.